Etoposide Solution for Injection Shortage

• • Etoposide solution, Accord, 20 mg/mL, 25 mL multiple dose vial, 1 count, NDC 16729-0114-08
  • Etoposide solution, Accord, 20 mg/mL, 5 mL multiple dose vial, 1 count, NDC 16729-0114-31
  • Etoposide solution, Accord, 20 mg/mL, 50 mL multiple dose vial, 1 count, NDC 16729-0114-11
  • Etoposide solution, Fresenius Kabi, 20 mg/mL, 25 mL multiple dose vial, 1 count, NDC 63323-0104-25
  • Etoposide solution, Fresenius Kabi, 20 mg/mL, 5 mL multiple dose vial, 10 count, NDC 63323-0104-05
  • Etoposide solution, Fresenius Kabi, 20 mg/mL, 50 mL multiple dose vial, 1 count, NDC 63323-0104-50
  • Etoposide solution, Hikma, 20 mg/mL, 25 mL multiple dose vial, 1 count, NDC 00143-9511-01
  • Etoposide solution, Hikma, 20 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00143-9510-01
  • Etoposide solution, Hikma, 20 mg/mL, 50 mL multiple dose vial, 1 count, NDC 00143-9512-01

• • Accord has etoposide injection on shortage due to manufacturing delays.
  • Fresenius Kabi did not provide a reason for the shortage.
  • Hikma did not provide a reason for the shortage.
  • Teva stopped marketing etoposide injection in 2022.

• • There is insufficient supply for usual ordering

Estimated Resupply Dates

• • Accord has etoposide 20 mg/mL 25 mL and 50 mL vials on back order and the company cannot estimate a release date. The 5 mL vials are available in limited supply.
  • Fresenius Kabi has etoposide 20 mg/mL 5 mL, 25 mL, and 50 mL vials on back order and the company estimates a release date of late-May 2024.
  • Hikma has etoposide 20 mg/mL 5 mL, 25 mL, and 50 mL vials on back order and the company estimates a release date of late-May 2024.